Q2 FY2026 · ended Jun 30, 2026 · Revenue $0, -100.0% YoY · Filed Jul 27, 2026
Geovax Labs, Inc. (GOVX) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $0 and a net loss of $4.4 million. Free cash flow was -$3.7 million. As of Jun 30, 2026 it held $3.1 million in cash and investments and $323,141 in total debt.
Revenue
$0
-100.0% vs year-ago quarter
Net income
$-4.43M
+17.6% vs year-ago quarter
Operating cash flow
$-3.66M
+15.6% vs year-ago quarter
Free cash flow
$-3.66M
+15.8% vs year-ago quarter
EPS
—
Dividend per share
None
Shares outstanding
7.37M
-70.9% vs year-ago quarter
Net cash
$2.82M
Q2 FY2026
Operating margin
-635.8%
Q2 FY2025
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- GOVX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Smyrna, GA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 832489
- Former names
- DAUPHIN TECHNOLOGY INC (until Sep 20, 2006)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $852,282 |
| Operating income | -$4.4M | -$5.3M | -$4.4M | -$6.4M | -$5.4M |
| Net income | -$4.4M | -$5.3M | -$4.4M | -$6.3M | -$5.4M |
| Operating cash flow | -$3.7M | -$3.5M | -$5.0M | -$6.2M | -$4.3M |
| Free cash flow | -$3.7M | -$3.5M | -$5.0M | -$6.2M | -$4.3M |
| Total assets | $4.6M | $3.0M | $6.3M | $6.7M | $5.4M |
| Total liabilities | $2.9M | $2.5M | $2.5M | — | — |
| Stockholders' equity | $1.8M | $493,770 | $3.8M | $4.9M | $2.8M |
| Cash and investments | $3.1M | $1.3M | $3.1M | $5.0M | $3.1M |
| Total debt | $323,141 | $394,571 | $843,170 | — | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Shareholder vote results
|
Oct 27, 2026 | Oct 27, 2026 |
| 8-K |
Current report
Material agreement, New debt, Change to shareholder rights, Officer or director change, Regulation FD disclosure
|
Oct 27, 2026 | Oct 23, 2026 |
| 8-K |
Current report
Other events
|
Sep 10, 2026 | Sep 10, 2026 |
| 8-K |
Current report
Listing notice
|
Aug 28, 2026 | Aug 27, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Aug 28, 2026 | Aug 25, 2026 |
| 10-Q | Quarterly report | Jul 27, 2026 | Jun 30, 2026 |
All 1000 Geovax Labs, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.